Hepatitis Forums

Hepatitis C Main Forums => Hepatitis C Research News & Studies => Topic started by: Hep Editors on November 04, 2019, 11:47:32 am

Title: Providing Naloxone to People Who Inject Drugs During Hep C Care Drives Up Use
Post by: Hep Editors on November 04, 2019, 11:47:32 am

Providing naloxone to people who inject drugs (PWID) as part of their medical care for hepatitis C virus (HCV) drives up use of the opioid overdose reversal drug within the larger PWID community, the National AIDS Treatment Advocacy Project (NATAP) reports.

Researchers from the University of Maryland presented findings from the single-center ANCHOR study at the IDWeek meeting in Washington, DC, earlier this month. The study is assessing HCV treatment with Epclusa (sofosbuvir/velpatasvir) among PWID. Clinicians also offer participants the opportunity to receive the medication-assisted treatment with buprenorphine to treat opioid use disorder as well as pre-exposure prophylaxis (PrEP) against HIV.

For more...
https://www.hepmag.com/article/providing-naloxone-people-inject-drugs-hep-c-care-drives-use